Deferred Tax Assets, Valuation Allowance of Vistagen Therapeutics, Inc. from 31 Mar 2012 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Vistagen Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Mar 2012 to 31 Mar 2025.
  • Vistagen Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Mar 2025 was $77,681,000, a 28% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Vistagen Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $77,681,000 +$17,160,000 +28% 31 Mar 2025 10-K 17 Jun 2025 2025 FY
Q1 2024 $60,521,000 +$1,270,000 +2.1% 31 Mar 2024 10-K 17 Jun 2025 2025 FY
Q1 2023 $59,251,000 +$10,630,700 +22% 31 Mar 2023 10-K 11 Jun 2024 2024 FY
Q1 2022 $48,620,300 +$8,743,700 +22% 31 Mar 2022 10-K 28 Jun 2023 2023 FY
Q1 2021 $39,876,600 +$2,921,800 +7.9% 31 Mar 2021 10-K 23 Jun 2022 2022 FY
Q1 2020 $36,954,800 +$4,202,500 +13% 31 Mar 2020 10-K 29 Jun 2021 2021 FY
Q1 2019 $32,752,300 +$7,499,900 +30% 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q1 2018 $25,252,400 -$9,529,300 -27% 31 Mar 2018 10-K 25 Jun 2019 2019 FY
Q1 2017 $34,781,700 +$3,566,700 +11% 31 Mar 2017 10-K 26 Jun 2018 2018 FY
Q1 2016 $31,215,000 +$31,189,228 31 Mar 2016 10-K 29 Jun 2017 2017 FY
Q1 2015 $25,772* +$46,925 31 Mar 2015 10-K 24 Jun 2016 2016 FY
Q1 2014 $21,153* -$2,126 31 Mar 2014 10-K 29 Jun 2015 2015 FY
Q1 2013 $19,027* -$2,814 31 Mar 2013 10-K 25 Jun 2014 2014 FY
Q1 2012 $16,213* 31 Mar 2012 10-K 18 Jul 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.